Skip to main content

Table 2 Response rate in 70 patients

From: FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort

Responses

No. of patients

%

Complete response

1

1.4

Partial response

15

21.4

Stable disease

21

30

Progressive disease

33

47.2